EA202192907A1 - Моноклональное антитело, которое специфически связывается с gitr - Google Patents

Моноклональное антитело, которое специфически связывается с gitr

Info

Publication number
EA202192907A1
EA202192907A1 EA202192907A EA202192907A EA202192907A1 EA 202192907 A1 EA202192907 A1 EA 202192907A1 EA 202192907 A EA202192907 A EA 202192907A EA 202192907 A EA202192907 A EA 202192907A EA 202192907 A1 EA202192907 A1 EA 202192907A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gitr
monoclonal antibody
antibody
relates
specificly
Prior art date
Application number
EA202192907A
Other languages
English (en)
Inventor
Андрей Борисович УЛИТИН
Олеся Николаевна КОЗЛОВА
Александр Андреевич ГОРДЕЕВ
Ксения Михайловна БУРНЫШЕВА
Анастасия Николаевна ИШУТИНОВА
Александра Александровна СОЗОНОВА
Сергей Андреевич АГЕЕВ
Александр Николаевич ДОРОНИН
Владимир Сергеевич ЦЫМПИЛОВ
Иван Владимирович МИТРОШИН
Валерий Владимирович СОЛОВЬЕВ
Яков Юрьевич УСТЮГОВ
Роман Алексеевич ИВАНОВ
Дмитрий Валентинович МОРОЗОВ
Original Assignee
Закрытое Акционерное Общество "Биокад"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закрытое Акционерное Общество "Биокад" filed Critical Закрытое Акционерное Общество "Биокад"
Publication of EA202192907A1 publication Critical patent/EA202192907A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к области биотехнологии, а именно к антителам или их антигенсвязывающим фрагментам, а также их применению. Более конкретно, настоящее изобретение относится к моноклональным антителам, которые специфически связываются с GITR. Изобретение также относится к нуклеиновой кислоте, кодирующей данное антитело или его антигенсвязывающему фрагменту, вектору экспрессии, способу получения антитела и применению антитела для лечения заболеваний или нарушений, связанных с GITR.
EA202192907A 2019-04-23 2020-04-23 Моноклональное антитело, которое специфически связывается с gitr EA202192907A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019112296A RU2734432C1 (ru) 2019-04-23 2019-04-23 Моноклональное антитело, которое специфически связывается с GITR
PCT/RU2020/050080 WO2020218951A2 (ru) 2019-04-23 2020-04-23 Моноклональное антитело, которое специфически связывается с gitr

Publications (1)

Publication Number Publication Date
EA202192907A1 true EA202192907A1 (ru) 2022-01-25

Family

ID=69821666

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192907A EA202192907A1 (ru) 2019-04-23 2020-04-23 Моноклональное антитело, которое специфически связывается с gitr

Country Status (22)

Country Link
US (1) US20220213209A1 (ru)
EP (1) EP3964525A4 (ru)
JP (1) JP2022532991A (ru)
KR (1) KR20220010501A (ru)
CN (1) CN110903392B (ru)
AR (1) AR118763A1 (ru)
AU (1) AU2020261207A1 (ru)
BR (1) BR112021021281A2 (ru)
CA (1) CA3137822A1 (ru)
CL (1) CL2021002792A1 (ru)
CO (1) CO2021014153A2 (ru)
EA (1) EA202192907A1 (ru)
IL (1) IL287531A (ru)
JO (1) JOP20210286A1 (ru)
MA (2) MA54969A1 (ru)
MX (1) MX2021012962A (ru)
PE (1) PE20220144A1 (ru)
RU (1) RU2734432C1 (ru)
TW (1) TWI803718B (ru)
UY (1) UY38672A (ru)
WO (1) WO2020218951A2 (ru)
ZA (1) ZA202109374B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111732658B (zh) * 2020-06-28 2022-04-26 英诺湖医药(杭州)有限公司 一组gitr单克隆抗体及其医药用途
CN112362876B (zh) * 2020-08-06 2023-12-15 武汉天德生物科技有限公司 一种检测早期老年痴呆症的胶体金试纸条及其制备方法
CN112540179B (zh) * 2020-08-06 2023-07-07 武汉天德生物科技有限公司 一种测试ApoE4蛋白含量的ELISA试剂盒
CN111763257B (zh) * 2020-09-01 2020-12-15 北京百奥赛图基因生物技术有限公司 抗gitr抗体及其用途
CN114891112A (zh) * 2020-12-31 2022-08-12 中元汇吉生物技术股份有限公司 特异性结合人IgG4的蛋白及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
RU2369636C2 (ru) * 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US20100104564A1 (en) 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
EP1899477A4 (en) 2005-07-01 2010-01-20 Medimmune Inc INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS
PL3023438T3 (pl) * 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
CN108064242B (zh) * 2014-05-28 2022-10-21 阿吉纳斯公司 抗gitr抗体和其使用方法
HUE047385T2 (hu) * 2014-06-06 2020-04-28 Bristol Myers Squibb Co Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai
EP3244926A4 (en) * 2015-01-14 2018-06-27 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
WO2017068186A1 (en) 2015-10-22 2017-04-27 Ablynx Nv Gitr agonists
CA3007022A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
MA45233A (fr) 2016-06-10 2019-04-17 Regeneron Pharma Anticorps anti-gitr et leurs utilisations
WO2018005950A1 (en) * 2016-07-01 2018-01-04 Five Prime Therapeutics, Inc. Combined anti tumor therapy with a gitr agonist and cpg
EP3497126A4 (en) * 2016-08-12 2020-04-08 Janssen Biotech, Inc. ANTIBODIES OF FC MODIFIED ANTI-TNFR SUPERFAMILY HAVING IMPROVED AGONIST ACTIVITY AND METHODS OF USE THEREOF
CA3042727A1 (en) * 2016-11-19 2018-05-24 Potenza Therapeutics, Inc. Anti-gitr antigen-binding proteins and methods of use thereof
CA3054885A1 (en) * 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途

Also Published As

Publication number Publication date
PE20220144A1 (es) 2022-01-27
UY38672A (es) 2020-10-30
ZA202109374B (en) 2022-12-21
MX2021012962A (es) 2021-12-15
JP2022532991A (ja) 2022-07-21
MA55390A1 (fr) 2022-05-31
AR118763A1 (es) 2021-10-27
CN110903392B (zh) 2024-02-13
WO2020218951A2 (ru) 2020-10-29
TWI803718B (zh) 2023-06-01
CO2021014153A2 (es) 2021-10-29
TW202100554A (zh) 2021-01-01
RU2734432C1 (ru) 2020-10-16
BR112021021281A2 (pt) 2022-03-08
KR20220010501A (ko) 2022-01-25
MA54969A1 (fr) 2022-08-31
CA3137822A1 (en) 2020-10-29
WO2020218951A3 (ru) 2020-12-24
CL2021002792A1 (es) 2022-06-24
JOP20210286A1 (ar) 2023-01-30
AU2020261207A1 (en) 2021-12-23
MA55390B1 (fr) 2022-10-31
EP3964525A2 (en) 2022-03-09
CN110903392A (zh) 2020-03-24
EP3964525A4 (en) 2022-12-28
IL287531A (en) 2021-12-01
US20220213209A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201692192A1 (ru) СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ
EA202091747A1 (ru) Составы антитела b7-h4
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
EA201892522A1 (ru) Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
JP2020507578A5 (ru)
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
RU2014127287A (ru) Антитела, используемые для пассивной вакцинации против гриппа
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202192810A1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA202091569A1 (ru) Моноклональные антитела и способы их применения
MX2022003833A (es) Anticuerpos anti-kir3dl3 y sus usos.
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
EA202191173A1 (ru) Моноклональное антитело, которое специфически связывается с cd20
EA201891800A1 (ru) Антитела к цитруллинированным hla-полипептидам и их применение
EA202090864A1 (ru) Моноклональное антитело к il-5r
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.
EA202091053A1 (ru) Модифицированные c- и ch1-домены